Literature DB >> 11595300

Considering genetic profiles in functional studies of immune responsiveness to HIV-1.

M Carrington1, G Nelson, S J O'Brien.   

Abstract

Over the last two decades HIV-1 has spread worldwide and has now surpassed malaria as the leading cause of infectious disease mortality in adults (http://www.who.int/infectious-disease-report/pages/ch1text.html). The clinical course and outcome of HIV-1 infection are highly variable among individuals. Most individuals infected with HIV develop AIDS within 10 years. However about 1-5% remain relatively healthy for 15 years or more (long-term nonprogressors), while others progress to AIDS within the first 2-3 years after infection (rapid progressors). A small number of individuals are resistant to infection, while some individuals appear to eliminate the virus. Factors that influence susceptibility to infection and rate of disease progression are a combination of viral, host, and environmental determinants. With few exceptions, genetic resistance to infectious diseases is likely to involve a complex array of host genetic effects involving variants that have very subtle, but significant consequences on gene expression or protein function. We have gained considerable insight into the genetic effects on HIV-1 disease, yet we likely have uncovered only a fraction of the total picture. The greater our knowledge of various effects on HIV disease, the more likely we will be able to predict disease outcome on an individual-by-individual basis. While this may seem obvious, there is no standard practice of taking into account the genetic profile (i.e. genotypes at loci known to associate with rate of AIDS progression) of subjects used in functional studies of immune responsiveness to HIV-1. Here, we propose an approach for assessing overall genetic risk on an individual basis, and suggest that this information be considered when selecting comparison groups in studies of immune responses to HIV and/or in the interpretation of data derived from such studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595300     DOI: 10.1016/s0165-2478(01)00275-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  13 in total

Review 1.  Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS.

Authors:  Koushik Chatterjee
Journal:  J Genet       Date:  2010-04       Impact factor: 1.166

2.  Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study.

Authors:  Mehdi Nouraie; Sergei Nekhai; Victor R Gordeuk
Journal:  Sex Transm Infect       Date:  2012-05-24       Impact factor: 3.519

3.  Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression.

Authors:  Gabriela Bleiber; Margaret May; Raquel Martinez; Pascal Meylan; Jürg Ott; Jacques S Beckmann; Amalio Telenti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis : CSF Biomarkers of SIV Encephalitis.

Authors:  Stephanie J Bissel; Julia Kofler; Julia Nyaundi; Michael Murphey-Corb; Stephen R Wisniewski; Clayton A Wiley
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-08       Impact factor: 4.147

5.  CD4+ CD25+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes.

Authors:  Douglas S Kwon; Mathieu Angin; Tomoyuki Hongo; Kenneth M Law; Jessica Johnson; Filippos Porichis; Meghan G Hart; David F Pavlik; Daniel P Tighe; Daniel G Kavanagh; Hendrik Streeck; Marylyn M Addo; Daniel E Kaufmann
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

6.  Multicenter initiative seeking critical genes in respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Craig S Derkay; Suzanne M Leal; Joseph Donfack; Garth D Ehrlich; J Christopher Post
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

7.  CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Authors:  Sunil K Ahuja; Hemant Kulkarni; Gabriel Catano; Brian K Agan; Jose F Camargo; Weijing He; Robert J O'Connell; Vincent C Marconi; Judith Delmar; Joseph Eron; Robert A Clark; Simon Frost; Jeffrey Martin; Seema S Ahuja; Steven G Deeks; Susan Little; Douglas Richman; Frederick M Hecht; Matthew J Dolan
Journal:  Nat Med       Date:  2008-03-30       Impact factor: 53.440

8.  Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection.

Authors:  Angela Ciuffi; Gabriela Bleiber; Miguel Muñoz; Raquel Martinez; Corinne Loeuillet; Manuela Rehr; Marek Fischer; Huldrych F Günthard; Annette Oxenius; Pascal Meylan; Sebastian Bonhoeffer; Didier Trono; Amalio Telenti
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 9.  Elite control of HIV infection: implications for vaccine design.

Authors:  B M Baker; B L Block; A C Rothchild; B D Walker
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

Review 10.  Hepatitis C virus adaptation to T-cell immune pressure.

Authors:  A Plauzolles; M Lucas; S Gaudieri
Journal:  ScientificWorldJournal       Date:  2013-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.